HomeInsightsStock Comparison

Eris Lifesciences Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Eris Lifesciences Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1520 as of 21 May 10:33.
  • The P/E Ratio of ERIS Lifesciences Ltd changed from 16.9 on March 2020 to 29.2 on March 2024 . This represents a CAGR of 11.56% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of ERIS Lifesciences Ltd changed from ₹ 5003 crore on March 2020 to ₹ 11442 crore on March 2024 . This represents a CAGR of 17.99% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of ERIS Lifesciences Ltd for the Mar '25 is ₹ 713.31 crore as compare to the Dec '24 revenue of ₹ 731.67 crore. This represent the decline of -2.51% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of ERIS Lifesciences Ltd for the Mar '25 is ₹ 260.4 crore as compare to the Dec '24 ebitda of ₹ 254.53 crore. This represent the growth of 2.31% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of ERIS Lifesciences Ltd changed from ₹ 93.65 crore to ₹ 102.35 crore over 8 quarters. This represents a CAGR of 4.54% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of ERIS Lifesciences Ltd changed from 13.76 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 16.65 % on March 2020 to 58.86 % on March 2024 . This represents a CAGR of 28.73% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About ERIS Lifesciences Ltd

  • Eris Lifesciences Limited was incorporated on January 25, 2007.
  • Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
  • Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
  • The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
  • It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors.

About Jagsonpal Pharmaceuticals Ltd

  • Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
  • The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
  • Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
  • It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
  • In 1994, the company has also promoted Aresco Financial Services, a new financial company.

ERIS Lifesciences Ltd News Hub

News

Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarte...

Read more

20 May 2025 13:08

News

ERIS Lifesciences to hold board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2...

Read more

14 May 2025 16:22

News

Eris Lifesciences allots 33,287 equity shares under ESOP

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-...

Read more

06 Mar 2025 13:17

News

Eris Lifesciences avails credit facility of Rs 1,000 cr

Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahi...

Read more

21 Feb 2025 09:22

News

Board of ERIS Lifesciences recommends Interim Dividend

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held...

Read more

07 Feb 2025 16:36

News

ERIS Lifesciences schedules board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 Februa...

Read more

05 Feb 2025 14:58

Jagsonpal Pharmaceuticals Ltd News Hub

News

Board of Jagsonpal Pharmaceuticals recommends final dividend

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meet...

Read more

07 May 2025 09:28

News

Jagsonpal Pharmaceuticals to announce Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

30 Apr 2025 10:51

News

Jagsonpal Pharmaceuticals allots 39,850 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 39,850 equity shares under ESOP. With this allotmen...

Read more

21 Apr 2025 14:14

News

Jagsonpal Pharmaceuticals allots 11,575 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 11,575 equity shares under ESOP. Consequent to the ...

Read more

13 Mar 2025 18:58

News

Jagsonpal Pharmaceuticals allots 22,150 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 22,150 equity shares of Rs. 2/- each under JPL ESOP...

Read more

17 Feb 2025 12:41

News

Jagsonpal Pharma gains after reporting strong Q3 numbers

Revenue from operations surged 56.7% to Rs 74.03 crore recorded in the quarter ended 31 De...

Read more

23 Jan 2025 12:45

SWOT Analysis Of ERIS Lifesciences Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Jagsonpal Pharmaceuticals Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

BlinkX Score for ERIS Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Jagsonpal Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of ERIS Lifesciences Ltd is 20,002 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,398 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd?

As of May 21, 2025, the ERIS Lifesciences Ltd stock price is INR ₹1468.75. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹210.45.

How do dividend payouts of ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions